Imatinib mesylate has become the gold standard front-line treatment of chronic myelogenous leukemia through its ability to inhibit ABL tyrosine kinase. Resistance to this inhibition may occur. We investigated the role of the K247R polymorphism in persistent sensitivity.
Figures & Tables
Article Information
Vol. 91 No. 1 (2006): January, 2006 : Letters to the Editor
FE Nicolini, K Chabane, JM Cayuela, P Rousselot, X Thomas, S Hayette. The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib. Haematologica 2006; 91(1):137-138; https://doi.org/10.3324/%x.
To create an adaptation, translation, or derivative of the
original work, for commercial e-prints and printed articles further permission is required.
For information contact: marketing@haematologica.org
Other types of copyright management, can be agreed with the Editorial office.
